학술논문

KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine
Document Type
article
Source
npj Vaccines. 7(1)
Subject
Biomedical and Clinical Sciences
Immunology
Cancer
Orphan Drug
Vaccine Related
Rare Diseases
Infectious Diseases
Biotechnology
Immunization
Emerging Infectious Diseases
Prevention
HIV/AIDS
3.4 Vaccines
Prevention of disease and conditions
and promotion of well-being
Infection
Good Health and Well Being
Medical microbiology
Language
Abstract
Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the "low-hanging fruit" that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole cause of Kaposi sarcoma, which primarily afflicts resource-poor and socially marginalized populations. This review summarizes a recent NIH-sponsored workshop's findings on the epidemiology and biology of KSHV as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.